OKYO Pharma Ltd (NASDAQ:OKYO) announced that its CEO Robert Dempsey purchased 15,000 ordinary shares of the clinical-stage biopharmaceutical company on the Nasdaq.
The shares were acquired at a price of $1.54 each, representing a total purchase value of about $23,100.